{"title":"关于代谢相关脂肪肝患者肝活检的问题","authors":"D. Venidiktova, A. Borsukov","doi":"10.47026/2413-4864-2022-4-12-26","DOIUrl":null,"url":null,"abstract":"The aim of the work was to evaluate the possibility of replacing liver biopsy with other methods of examination in patients with metabolically associated fatty liver disease. All patients were examined according to a single diagnostic algorithm consisting of four stages: physical, laboratory, instrumental (using non-invasive bioimpedansometry, multiparametric ultrasound examination, dual-energy X-ray absorptiometry in the \"Whole body\" mode, computer and magnetic resonance imaging), histological (evaluation of liver micropreparations on the SAF scale). the patients were divided into three groups, taking into account the results of histological examination of biopsies on the SAF scale: group 1 – patients with hepatic steatosis without signs of inflammation, fibrosis (n = 56, 53.9%); group 2 – patients with steatohepatitis and clinically insignificant hepatic fibrosis F0-F1 (n = 30, 28.8%); group 3 – patients with steatohepatitis and clinically significant liver fibrosis F2-F3 (n = 16, 15.4%). the correlation of findings obtained by the histological examination of liver biopsies and the data of ultrasound quantitative liver steatometry is high – r = 0.95 (for liver steatosis S1), r = 0.84 (for liver steatosis S2), r = 0.91 (for liver steatosis S3); ultrasonic shear wave elastography – r = 0.84 (for clinically insignificant liver fibrosis F0-F1), r = 0.88 (for clinically significant liver fibrosis F2-F3). the data obtained using dual-energy X-ray absorptiometry in the \"Whole Body\" mode quantitatively reflect the state of the patient's metabolic status, they can be evaluated in dynamics due to low radiation load. Thus, the diagnostic complex consisting of assessing the level of hepatic transaminases, multiparametric ultrasound examination and dual-energy X-ray absorptiometry in the \"Whole body\" mode is optimal to examine the patients who have contraindications to liver biopsy or completely refuse to pass this study. in case of the patient's consent, absence of contraindications, as well as in the presence of a number of diffuse liver diseases, histological examination is recommended to identify and to assess in detail the dystrophic, inflammatory, sclerotic, regenerative processes.","PeriodicalId":249759,"journal":{"name":"Acta medica Eurasica","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ON THE ISSUE OF LIVER BIOPSY IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE\",\"authors\":\"D. Venidiktova, A. Borsukov\",\"doi\":\"10.47026/2413-4864-2022-4-12-26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of the work was to evaluate the possibility of replacing liver biopsy with other methods of examination in patients with metabolically associated fatty liver disease. All patients were examined according to a single diagnostic algorithm consisting of four stages: physical, laboratory, instrumental (using non-invasive bioimpedansometry, multiparametric ultrasound examination, dual-energy X-ray absorptiometry in the \\\"Whole body\\\" mode, computer and magnetic resonance imaging), histological (evaluation of liver micropreparations on the SAF scale). the patients were divided into three groups, taking into account the results of histological examination of biopsies on the SAF scale: group 1 – patients with hepatic steatosis without signs of inflammation, fibrosis (n = 56, 53.9%); group 2 – patients with steatohepatitis and clinically insignificant hepatic fibrosis F0-F1 (n = 30, 28.8%); group 3 – patients with steatohepatitis and clinically significant liver fibrosis F2-F3 (n = 16, 15.4%). the correlation of findings obtained by the histological examination of liver biopsies and the data of ultrasound quantitative liver steatometry is high – r = 0.95 (for liver steatosis S1), r = 0.84 (for liver steatosis S2), r = 0.91 (for liver steatosis S3); ultrasonic shear wave elastography – r = 0.84 (for clinically insignificant liver fibrosis F0-F1), r = 0.88 (for clinically significant liver fibrosis F2-F3). the data obtained using dual-energy X-ray absorptiometry in the \\\"Whole Body\\\" mode quantitatively reflect the state of the patient's metabolic status, they can be evaluated in dynamics due to low radiation load. Thus, the diagnostic complex consisting of assessing the level of hepatic transaminases, multiparametric ultrasound examination and dual-energy X-ray absorptiometry in the \\\"Whole body\\\" mode is optimal to examine the patients who have contraindications to liver biopsy or completely refuse to pass this study. in case of the patient's consent, absence of contraindications, as well as in the presence of a number of diffuse liver diseases, histological examination is recommended to identify and to assess in detail the dystrophic, inflammatory, sclerotic, regenerative processes.\",\"PeriodicalId\":249759,\"journal\":{\"name\":\"Acta medica Eurasica\",\"volume\":\"20 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta medica Eurasica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47026/2413-4864-2022-4-12-26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Eurasica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47026/2413-4864-2022-4-12-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
这项工作的目的是评估在代谢相关脂肪肝患者中用其他检查方法替代肝活检的可能性。所有患者均按照单一诊断算法进行检查,该诊断算法包括四个阶段:物理、实验室、仪器(使用无创生物阻抗测量、多参数超声检查、“全身”模式双能x线吸收仪、计算机和磁共振成像)、组织学(在SAF量表上评估肝脏微制剂)。根据SAF评分的组织学检查结果,将患者分为三组:1组-无炎症、纤维化体征的肝脂肪变性患者(n = 56, 53.9%);2组-脂肪性肝炎伴临床不明显肝纤维化F0-F1患者(n = 30, 28.8%);3组:脂肪性肝炎伴临床显著肝纤维化F2-F3患者(n = 16, 15.4%)。肝活检组织学检查结果与超声定量肝脂肪测量数据相关性高,r = 0.95(肝脂肪变性S1), r = 0.84(肝脂肪变性S2), r = 0.91(肝脂肪变性S3);超声横波弹性成像r = 0.84(临床不明显肝纤维化F0-F1), r = 0.88(临床明显肝纤维化F2-F3)。双能x线吸收仪在“全身”模式下获得的数据定量反映了患者的代谢状态,由于低辐射负荷,可以动态评估。因此,评估肝转氨酶水平、多参数超声检查和双能x线吸收仪“全身”模式的诊断复合体最适合检查有肝活检禁忌症或完全拒绝通过本研究的患者。在患者同意、无禁忌症以及存在一些弥漫性肝病的情况下,建议进行组织学检查,以确定和详细评估营养不良、炎症、硬化和再生过程。
ON THE ISSUE OF LIVER BIOPSY IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE
The aim of the work was to evaluate the possibility of replacing liver biopsy with other methods of examination in patients with metabolically associated fatty liver disease. All patients were examined according to a single diagnostic algorithm consisting of four stages: physical, laboratory, instrumental (using non-invasive bioimpedansometry, multiparametric ultrasound examination, dual-energy X-ray absorptiometry in the "Whole body" mode, computer and magnetic resonance imaging), histological (evaluation of liver micropreparations on the SAF scale). the patients were divided into three groups, taking into account the results of histological examination of biopsies on the SAF scale: group 1 – patients with hepatic steatosis without signs of inflammation, fibrosis (n = 56, 53.9%); group 2 – patients with steatohepatitis and clinically insignificant hepatic fibrosis F0-F1 (n = 30, 28.8%); group 3 – patients with steatohepatitis and clinically significant liver fibrosis F2-F3 (n = 16, 15.4%). the correlation of findings obtained by the histological examination of liver biopsies and the data of ultrasound quantitative liver steatometry is high – r = 0.95 (for liver steatosis S1), r = 0.84 (for liver steatosis S2), r = 0.91 (for liver steatosis S3); ultrasonic shear wave elastography – r = 0.84 (for clinically insignificant liver fibrosis F0-F1), r = 0.88 (for clinically significant liver fibrosis F2-F3). the data obtained using dual-energy X-ray absorptiometry in the "Whole Body" mode quantitatively reflect the state of the patient's metabolic status, they can be evaluated in dynamics due to low radiation load. Thus, the diagnostic complex consisting of assessing the level of hepatic transaminases, multiparametric ultrasound examination and dual-energy X-ray absorptiometry in the "Whole body" mode is optimal to examine the patients who have contraindications to liver biopsy or completely refuse to pass this study. in case of the patient's consent, absence of contraindications, as well as in the presence of a number of diffuse liver diseases, histological examination is recommended to identify and to assess in detail the dystrophic, inflammatory, sclerotic, regenerative processes.